Promacta Study Halted Due to Increased Risk for Portal Venous Thrombosis in Patients With Liver Disease
This is a discussion on Promacta Study Halted Due to Increased Risk for Portal Venous Thrombosis in Patients With Liver Disease within the Other Clinical Pharmacy News forum, part of the Industry News and Updates category; In the ELEVATE study, 4% of patients receiving eltrombopag and 1% of those receiving placebo developed portal venous thrombosis. Medscape ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
05-14-2010, 09:29 AM
|
|||
|
|||
Promacta Study Halted Due to Increased Risk for Portal Venous Thrombosis in Patients With Liver Disease
In the ELEVATE study, 4% of patients receiving eltrombopag and 1% of those receiving placebo developed portal venous thrombosis.
Medscape Medical News More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA Urges Caution in Interpreting Study Linking Stimulants to Increased Risk for Sudden Death in Children | industry_news | Other Clinical Pharmacy News | 0 | 06-15-2009 07:54 PM |
| Interferons and definition of compensated liver disease | participant1 | Managed Care Issues for Injectable Drugs | 2 | 12-04-2008 01:21 PM |
| Cancer Incidence Increased After Liver Transplantation | industry_news | Other Clinical Pharmacy News | 0 | 10-13-2008 02:29 PM |
| Nonfasting Triglyceride Levels Associated With an Increased Risk for Cardiovascular Disease | industry_news | Other Clinical Pharmacy News | 0 | 07-17-2008 05:35 PM |
| Liver Cancer Surgery Benefits Patients With Multiple Tumors, Portal Hypertension | industry_news | Other Clinical Pharmacy News | 0 | 07-17-2008 02:59 PM |
© 2008 DrugManagementForum™ powered by |
 |